Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma

BACKGROUND: Pembrolizumab is an anti- Programmed Death 1 (PD-1) antibody approved in melanoma, non-small cell lung cancer and investigated in malignant pleural mesothelioma. The most frequent immunotherapy related autoimmune reactions include dermatitis, pneumonitis, colitis, hypophysitis, uveitis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bickel, Angelika, Koneth, Irene, Enzler-Tschudy, Annette, Neuweiler, Jörg, Flatz, Lukas, Früh, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992260/
https://www.ncbi.nlm.nih.gov/pubmed/27543082
http://dx.doi.org/10.1186/s12885-016-2718-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992260/
https://www.ncbi.nlm.nih.gov/pubmed/27543082
http://dx.doi.org/10.1186/s12885-016-2718-y

Ejemplares similares